Improving cognitive outcome in cerebral malaria: insights from clinical and experimental research.

Authors:
Address: Postgraduate Program in Health Sciences: Infectious Diseases and Tropical Medicine, Medical School, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. alines.miranda@hotmail.com
Journal:


Publication:

abstract

cerebral malaria (CM) is a clinical syndrome defined by the World Health Organization (WHO) as a potentially reversible diffuse encephalopathy characterized mainly by coma and the presence of asexual forms of Plasmodium falciparum parasites in peripheral blood smears in the absence of other causes of encephalopathy. A wide range of clinical manifestations follows the disease including cognitive, behavioral and motor dysfunctions, seizures and coma. The underlying mechanisms of CM pathogenesis remain incompletely understood although vascular, immunological and metabolic changes have been described. The classical treatment of CM is based on the administration of antimalarial drugs, especially chloroquine and artemisinin derivates as artesunate. Even with treatment, 15 to 20% of children with CM die and approximately 10 to 17% of those who survive remain with significant long-term cognitive impairment. In this context, neuroprotective and adjuvant therapies have been recently investigated in clinical and experimental studies of CM in an attempt to improve cognitive outcome. A poor understanding of pathophysiological mechanisms, properties of compounds used and patient selection have contributed to the lack of success of these interventions. This review discusses clinical aspects of cognitive sequelae, possible mechanisms involved in the brain injury, perspectives and limitations regarding the pharmacological strategies to improve cognitive outcome in CM.



Related Articles
Review [Combined antimalarial therapy using artemisinin].
Parassitologia. 2004
Review [Combined antimalarial therapy using artemisinin].
Majori G. Parassitologia. 2004 Jun; 46(1-2):85-7.
Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy.
PLoS Pathog. 2010
Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy.
Reis PA, Comim CM, Hermani F, Silva B, Barichello T, Portella AC, Gomes FC, Sab IM, Frutuoso VS, Oliveira MF, et al. PLoS Pathog. 2010 Jun 24; 6(6):e1000963. Epub 2010 Jun 24.
Review Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome.
Pediatr Res. 2010
Review Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome.
Idro R, Marsh K, John CC, Newton CR. Pediatr Res. 2010 Oct; 68(4):267-74.
Review Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
Am J Trop Med Hyg. 2004
Review Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
Breman JG, Alilio MS, Mills A. Am J Trop Med Hyg. 2004 Aug; 71(2 Suppl):1-15.
Review Cerebral malaria.
J Neurol Neurosurg Psychiatry....
Review Cerebral malaria.
Newton CR, Hien TT, White N. J Neurol Neurosurg Psychiatry. 2000 Oct; 69(4):433-41.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.